186 GSK Annual Report 2017 Notes to the financial statements continued 20.
Investments in associates and joint ventures Joint 2017 Joint 2016 ventures Associates Total ventures Associates Total m m m m m m At 1 January 19 244 263 20 187 207 Exchange adjustments 2 10 12 4 41 45 Additions 15 15 3 8 11 Disposals 92 92 Distributions received 1 1 2 2 1 3 Other movements 2 2 2 2 Loss profit after tax recognised in the consolidated income statement 3 16 13 4 9 5 At 31 December 13 170 183 19 244 263 The Group held one significant associate at 31 December 2017, Innoviva, Inc. At 31 December 2017, the Group owned 32 million shares or 31.4% of Innoviva, which is a biopharmaceutical company listed on NASDAQ.
Innoviva partnered with GSK in the development of the long acting beta agonist vilanterol and currently receives royalty income from sales of products that contain this component, namely Relvar Breo Ellipta, Anoro Ellipta and Trelegy Ellipta.
The remaining 85% of the economic interest in these royalties will be due to Theravance Biopharma Inc. a company spun out of Innoviva in 2014, in which the Group holds 17.8% of the common stock.
The investment in Innoviva had a market value of 336 million at 31 December 2017 2016 278 million.
In 2017, the Group divested its shareholdings in two associates, see Note 38, Acquisitions and disposals.
Summarised balance sheet information, based on results information, in respect of Innoviva is set out below: At 31 December At 31 December 2017 2016 m m Non-current assets 124 146 Current assets 148 160 Current liabilities 26 16 Non-current liabilities 426 575 Net liabilities 180 285 2017 2016 m m Interest in associated undertaking 57 84 Goodwill 86 84 Fair value and other adjustments 118 138 Carrying value at 31 December 147 138
